Evidence map›Paper›PMID 35061242›Full record

ReviewNetherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation2022

Immune checkpoint inhibitor-associated myocarditis : Case reports and a review of the literature.

T E Osinga, S F Oosting, P van der Meer, R A de Boer, B C Kuenen, A Rutgers, L Bergmann, T H Oude Munnink, M Jalving, M van Kruchten

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Reliability and applicability of theEuropean journal of applied physiology · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

T E OsingaDepartment of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
S F OostingDepartment of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
P van der MeerDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
R A de BoerDepartment of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
B C KuenenDepartment of Internal Medicine, Martini Hospital, Groningen, The Netherlands.
A RutgersDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
L BergmannMedical Clinic II, J.W. Goethe University, Frankfurt, Germany.
T H Oude MunninkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
M JalvingDepartment of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
M van KruchtenDepartment of Medical Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. m.van.kruchten@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly recognised to effectuate long-lasting therapeutic responses in solid tumours. However, ICI therapy can also result in various immune-related adverse events, such as ICI-associated myocarditis, a rare but serious complication. The clinical spectrum is wide and includes asymptomatic patients and patients with fulminant heart failure, making it challenging to diagnose this condition. Furthermore, the optimal diagnostic algorithm and treatment of ICI-associated myocarditis is unknown. In this review, we describe two cases on both ends of the spectrum and discuss the challenges in recognising, diagnosing and treating ICI-associated myocarditis.

Indexed as

Associated myocarditisCardiac biomarkersCardio-oncologyICI-associated myocarditisImmune checkpoint inhibitor

Identifiers

PMID35061242
PMCPMC9123105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.